Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Emmaus Life Sciences, Inc.
- Market Cap
- Unavailable
- Price
- $0.0321
- % Change (Daily % change from the live per-ticker quote feed.)
- +22.99%
- Volume
- 847.1K
About
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Quick stats
Shares outstanding—
Computed float42.8M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000822370
AI Summary
AI-generated1/4
majorbullishearnings
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported Q3 revenue of $6.3 million, up 124% year-over-year, driven by revenue recognition from its licensing deal with NeoImmuneTech.
The company swung to a net income of $1.3 million, or $0.02 per share, compared to a net loss of $1.1 million in the same period last year, aided by reduced operating expenses.
Despite the quarterly profitability, the company ended the period with $2.8 million in cash and a significant stockholders' deficit.
Red flags
- Balance sheet shows total liabilities ($82.5M) exceeding total assets ($16.4M)
- Company cites doubt about ability to continue as a going concern in forward-looking statements
- Accounts payable ($23.5M) significantly exceeds current assets ($6.0M) and cash ($2.8M)